lupus.bmj

Belimumab prevention against organ damage over 8 years and safety up to 13 years: three pooled open-label, long-term extension SLE studies

Objective Examine long-term glucocorticoid usage, safety and prevention of organ damage in patients with SLE treated with belimumab plus standard therapy (ST). Methods This post hoc analysis from ...
lupus.bmj

Lupus Science & Medicine®

is a global, peer-reviewed, open access lupus journal from LFA, publishing papers on all aspects of lupus and related diseases.
Lupus Science & Medicine

Reduced humoral response to recombinant zoster vaccine in patients with SLE: a prospective cohort study across immune-mediated inflammatory diseases

Patients with immune-mediated inflammatory diseases (IMIDs) are at increased risk of herpes zoster (HZ), particularly those ...
Lupus Science & Medicine

Inhibition of STING modulates dendritic cell responses and ameliorates podocyte injury in SLE

Background SLE features aberrant type I interferon production, with the stimulator of interferon genes (STING) pathway acting as a key upstream driver. However, its expression patterns in patients ...
lupus.bmj

International development of a lupus-specific instrument to assess cognitive symptoms in patients with SLE: Lupus Brain Fog Severity Scale (LBFSS) study

Introduction Cognitive symptoms such as ‘brain fog’ are frequent and disabling in patients with SLE. We aimed to develop and validate the Lupus Brain Fog Severity Scale (LBFSS), the first ...
lupus.bmj

Belimumab as a possible treatment for SLE-associated pulmonary arterial hypertension: the experience from a single centre

Objective To explore clinical outcomes associated with belimumab use in patients with SLE-associated pulmonary arterial hypertension (SLE-PAH). Methods We performed an ambispective cohort study of 10 ...
lupus.bmj

Beyond renal response: sustained systemic disease control protects against adverse long-term outcomes in lupus nephritis

Objectives Lupus Low Disease Activity State (LLDAS) and Definition of Remission in SLE (DORIS) are associated with improved outcomes in SLE; however, their value in lupus nephritis (LN) remains ...
lupus.bmj

Comparison of BAFF and type I IFN activity in blood and placenta in SLE and healthy pregnancies

Objective To examine B cell-activating factor (BAFF) and type I interferon (IFN) activity at the transcriptional and protein levels in blood and placental tissue in SLE compared with healthy ...
lupus.bmj

Double humanised lupus mouse model with human immune system and faecal microbiota from patients with SLE

Objective We aimed to create a double humanised lupus mouse model with a human immune system and faecal microbiota from patients with SLE. Methods We established the Double humanised SLE (DhuSLE) ...
lupus.bmj

Efficacy of belimumab in patients with SLE and haematological manifestations: retrospective analysis from the BeRLiSS 2.0 cohort

Objective To assess the effectiveness of belimumab (BEL) in improving anaemia, thrombocytopenia, lymphopenia and leucopenia in patients with SLE. Conclusion In this real-world cohort, BEL treatment ...
lupus.bmj

Real-world experience of anifrolumab treatment in patients with moderate-to-severe SLE: a retrospective study of patients in early access programmes

Objective The multinational ERYTHRO (NCT06046534) study investigated the experience of patients with moderate-to-severe SLE initiating anifrolumab treatment through routine clinical practice as part ...
lupus.bmj

PT5:05 Impact of HLA evolutionary divergence on peptide presentation and pathogen mimicry in the pathogenesis of SLE

Objectives Genetic variation within the human leukocyte antigen (HLA) region influences susceptibility across systemic autoimmune diseases (SADs). We investigated HLA class I and II allelic ...